Skip to main content
STARPHARMA HOLDINGS LIMITED logo

STARPHARMA HOLDINGS LIMITED — Investor Relations & Filings

Ticker · SPL ISIN · AU000000SPL0 LEI · 254900WRGE3OUSWGMB55 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,316 across all filing types
Latest filing 2025-11-13 AGM Information
Country AU Australia
Listing ASX SPL

About STARPHARMA HOLDINGS LIMITED

https://starpharma.com/

Starpharma Holdings Limited is a biopharmaceutical company focused on the development of dendrimer technology for pharmaceutical and life science applications. The company utilizes its proprietary DEP® (Dendrimer Enhanced Product) delivery platform to improve the performance of existing drugs by enhancing solubility, reducing toxicity, and providing targeted delivery. Its clinical-stage internal pipeline includes DEP® docetaxel, DEP® cabazitaxel, and DEP® irinotecan, primarily targeting oncology. Starpharma also markets VivaGel® BV, a non-antibiotic treatment and prevention for bacterial vaginosis, and VIRALEZE™, an antiviral nasal spray containing astodrimer sodium. The company collaborates with global pharmaceutical firms to apply its dendrimer technology to various therapeutic areas, including antibody-drug conjugates and radiopharmaceuticals.

Recent filings

Filing Released Lang Actions
AGM Chair address and CEO presentation 35 pages 4.3MB
AGM Information Classification · 100% confidence The document is an ASX announcement dated 14 November 2025 from Starpharma Holdings Limited. It contains the Chair's address and the CEO's presentation for the Annual General Meeting (AGM). The content includes strategic updates, partnership announcements, operational progress, and shareholder value discussions typically presented at an AGM. There is no indication that this is a full annual report or financial statements, but rather materials shared during the AGM event. The document length is substantial (15,000 characters), and it is clearly labeled as AGM Chair address and CEO presentation. Therefore, the document fits the category of AGM Information (AGM-R).
2025-11-13 English
Results of 2025 Annual General Meeting 2 pages 175.9KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 14 November 2025, detailing the results of the 2025 Annual General Meeting (AGM) of Starpharma Holdings Limited. It includes voting results on resolutions such as adoption of the remuneration report, re-election of a director, and approval of performance rights issuance. The document references compliance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, which govern disclosure of AGM voting results. The content is focused on the official announcement of shareholder voting outcomes rather than the AGM materials or presentations themselves. The document length is 6602 characters, which is consistent with a detailed voting results announcement rather than a full AGM presentation or annual report. Therefore, the document best fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-11-13 English
Quarterly Activities/Appendix 4C Cash Flow Report 6 pages 746.9KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'Quarterly Activities Report & Appendix 4C' for the quarter ended 30 September 2025 (Q1 FY26). It includes detailed operational highlights, partnership agreements, financial summaries including cash flow statements, and management commentary. The presence of Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B, confirms this is a quarterly report. The document contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement of a report or a certification, but the report itself with detailed financial and operational information. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2026
2025-10-27 English
Upfront payment of USD $5.5 million received from Genentech 2 pages 614.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement detailing the receipt of an upfront payment from Genentech under a license agreement. It discusses the collaboration and financial terms but does not contain financial statements, detailed financial performance data, or comprehensive report content. The document is approximately 7000 characters, which is relatively short and reads like a news release or update rather than a full financial report. There is no indication that this is an earnings release or a detailed investor presentation. The content focuses on a financing event (receipt of upfront payment) related to a licensing agreement, which fits best under Capital/Financing Update (CAP).
2025-10-21 English
Change of Director's Interest Notice - R Thomas 2 pages 306.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares held before and after the change, the nature of the change (on-market purchase), and the value of the transaction. This is a clear report of personal share transactions by a company director. The document length is 3694 characters, which is typical for such notices. There is no indication that this is an announcement of a report or a certification. Therefore, the document fits the definition of Director's Dealing (DIRS).
2025-10-20 English
Australian Microcap Investment Conference presentation 27 pages 2.8MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement containing a detailed presentation delivered by the CEO at the Australian Microcap Investment Conference. It includes extensive information about the company's strategy, technology platform, pipeline, partnerships, market outlook, and investment highlights. The content is structured as a presentation with slides and forward-looking statements, focusing on investor relations and company updates rather than financial statements or regulatory filings. There is no indication that this is a full annual or interim report, audit report, earnings release, or other regulatory filing. The document is clearly a presentation aimed at investors, providing detailed strategic and financial context. Therefore, the most appropriate classification is Investor Presentation (IP).
2025-10-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.